Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenetic Biosciences (XBIO) Share-based Compensation (2023 - 2025)

Xenetic Biosciences' Share-based Compensation history spans 4 years, with the latest figure at $13998.0 for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 44.25% year-over-year to $13998.0; the TTM value through Dec 2025 reached $64787.0, down 62.29%, while the annual FY2025 figure was $64787.0, 62.29% down from the prior year.
  • Share-based Compensation reached $13998.0 in Q4 2025 per XBIO's latest filing, down from $15855.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $77074.0 in Q1 2024 to a low of $13998.0 in Q4 2025.
  • Average Share-based Compensation over 3 years is $43307.2, with a median of $34816.0 recorded in 2024.
  • Peak YoY movement for Share-based Compensation: increased 11.94% in 2024, then tumbled 75.02% in 2025.
  • A 3-year view of Share-based Compensation shows it stood at $74578.0 in 2023, then plummeted by 66.33% to $25108.0 in 2024, then crashed by 44.25% to $13998.0 in 2025.
  • Per Business Quant, the three most recent readings for XBIO's Share-based Compensation are $13998.0 (Q4 2025), $15855.0 (Q3 2025), and $15683.0 (Q2 2025).